Paasa Logo
Kiniksa Pharmaceuticals International, plc logo
KNSANASDAQMarket openCloses 4:00pm ET

Kiniksa Pharmaceuticals International, plc

$75.41Last updated
+$0.07 (0.10%)Past day
Timezone

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) is trading at $75.41, about ₹7,241 at today's USD/INR rate, as of 25 Sep 2026, 2:25 PM ET, up 0.10% today. Indian residents can buy Kiniksa Pharmaceuticals International from India on Paasa under the RBI's Liberalised Remittance Scheme.

Quote

Open:$75.40
Previous close:$75.34
Volume:158.15K

Today's low

$74.53

Today's high

$75.99

52 week low

$35.20

52 week high

$82.94

KNSA opened at $75.40, closed previously at $75.34, and has traded between $35.20 and $82.94 over the past 52 weeks.

About

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.

Country
GB
CEO
Sanj K. Patel
Exchange listed on
NASDAQ
Industry
Medical - Pharmaceuticals
Base currency
USD
Full Time Employees
366
Sector
Healthcare
IPO date
24/05/2018

Key statistics

Avg. volume

682.60K

Market cap

$5.75B

P/E Ratio

70.49

Price-to-sales ratio

6.84

Enterprise value

$5.58B

Free cash flow yield

3.19%

Debt-to-equity ratio

0.01

Return on equity

13.65%

ROIC

9.71%

Beta

0.09

Dividend yield

0.00%

Last dividend

$0.00

Financial overview

Revenue

$677.56M

Earnings per share

$0.80

Free cash flow

$25.41M

Net profit margin

9.59%

Gross margin

54.49%

EBITDA

$90.42M

Revenue growth

60.09%

Similar securities

This is not an investment recommendation

How to buy Kiniksa Pharmaceuticals International from India

Indian residents can buy Kiniksa Pharmaceuticals International shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.

  1. Open a Paasa account

    Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.

  2. Add funds under LRS

    Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.

  3. Search for Kiniksa Pharmaceuticals International and place an order

    Find Kiniksa Pharmaceuticals International by name or by its ticker, KNSA, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. Kiniksa Pharmaceuticals International trades 7:00 pm – 1:30 am IST; orders can only execute during that window.

  4. Track holdings and download tax reports

    Follow your Kiniksa Pharmaceuticals International position in USD and INR. Kiniksa Pharmaceuticals International pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.

Read the full guide: how to invest in Kiniksa Pharmaceuticals International from India

Trading and taxes when buying Kiniksa Pharmaceuticals International from India

Trading and limits

Trading hours
9:30 am – 4:00 pm ET
LRS limit
$250,000Per financial year, under the RBI's Liberalised Remittance Scheme.

Tax for Indian residents

TCS on remittance
20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
Capital gains in India
12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
Dividends
NoneKiniksa Pharmaceuticals International does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained

Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.

FAQs

Can Indian residents buy Kiniksa Pharmaceuticals International stock?

Yes. Kiniksa Pharmaceuticals International (KNSA) has been listed on NASDAQ since 2018, in the Medical - Pharmaceuticals industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.

How much does one Kiniksa Pharmaceuticals International share cost in rupees?

One Kiniksa Pharmaceuticals International share is $75.41 — about ₹7,241 at a USD/INR rate of 96.02 on 24 Sep 2026. Both the Kiniksa Pharmaceuticals International price and the rupee rate move during the day, so the rupee cost changes with them.

What are the LRS and TCS rules for buying Kiniksa Pharmaceuticals International from India?

Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.

Can I buy whole shares of Kiniksa Pharmaceuticals International?

Yes. One Kiniksa Pharmaceuticals International share is $75.41, and you can buy as many whole shares as you like. You can also buy by amount rather than by quantity: there is no minimum trade size, and Paasa supports fractional investing in Kiniksa Pharmaceuticals International.

How are gains on Kiniksa Pharmaceuticals International shares taxed in India?

The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Kiniksa Pharmaceuticals International price. Paasa issues a capital-gains statement for your return.

Does Kiniksa Pharmaceuticals International pay a dividend?

No. Kiniksa Pharmaceuticals International does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.

When can I trade Kiniksa Pharmaceuticals International from India?

NASDAQ trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.

Is Kiniksa Pharmaceuticals International a United States company, and does that change how it is taxed?

Kiniksa Pharmaceuticals International trades on NASDAQ in US dollars, but the company is domiciled in United Kingdom. Kiniksa Pharmaceuticals International trades as an ordinary share listed directly in the US, not a depositary receipt. Some non-US companies list in the US through American Depositary Receipts, which can carry dividend withholding at the company's home-country rate. Your India-side capital-gains treatment is the same either way.

Do I have to declare Kiniksa Pharmaceuticals International shares in my Indian tax return?

Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Kiniksa Pharmaceuticals International holding, its cost and its closing value.

How do I sell Kiniksa Pharmaceuticals International and bring the money back to India?

You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.